Moody's Investors Service said that it's reviewing its ratings for drugmaker Merck & Co.'s and may downgrade them. Moody's cited Merck's plan to buy back about $7.5 billion worth of its shares over the next 12 months. Those repurchases are part of a new $15 billion share repurchase program approved by Merck's board.
Actavis has acquired a bacterial vaginosis gel developed by Valeant Pharmaceuticals. Actavis said it agreed to pay Valeant $55 million for its metronidazole gel product, which has not yet received marketing approval. The total includes both an upfront payment and payments related to sales targets.
Perosphere and Daiichi Sankyo have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a Phase 1 clinical trial testing the safety, tolerability, and effectiveness of PER977 to reverse the anticoagulant activity of Daiichi Sankyo’s edoxaban.
Merck & Co. reported lower first-quarter results and cut its 2013 profit forecast by 15 cents a share. Merck tried to reassure investors by announcing a huge share buyback, up to $15 billion worth of its stock, but its share price dropped nearly 3% in premarket trading after its revenue missed expectations.
There’s hope for patients with myotonic dystrophy. A new small-molecule has been shown to break up the protein-RNA clusters that cause the disease in living human cells, an important first step toward developing a pharmaceutical treatment for the as-yet untreatable disease.
Researchers have found a way to see synthetic nanostructures and molecules using a new type of super-resolution optical microscopy that does not require fluorescent dyes, representing a practical tool for biomedical and nanotechnology research.
Despite advances that have been made in sunscreen technology and growing public awareness of the need for sunscreen, recent data have found that the average U.S. lifetime risk of invasive melanoma has increased from 1 in 600 in 1960 to 1 in 50 in 2008.
Cells ingest proteins and engulf bacteria by a gymnastic, shape-shifting process called endocytosis. New research reveals, on the real-life scale of nanometers, how individual molecules work together during a single act of endocytosis.
Pfizer Inc.'s first-quarter net income rose 53% despite growing generic drug competition as the drugmaker benefited from a gain related to a joint venture with China. But the company's results still fell short of Wall Street's expectations, and Pfizer lowered its 2013 profit forecast.
Researchers using a stripped-down experimental system have exposed the possible function, in the healthy brain, of a mysterious molecule that has been strongly implicated in Parkinson's disease, a degenerative disorder of the central nervous system.
Merck & Co. will work with Pfizer Inc. to develop a new combination pill designed to treat Type 2 diabetes. The experimental pill will combine Merck's drug Januvia, Pfizer's experimental pill ertugliflozin, and metformin, an older diabetes drug.
Auxilium Pharmaceuticals Inc. announced the purchase of Actient Holdings LLC from private equity firm GTCR for $585 million. In the process Auxilium said it will get two testosterone drugs, impotence treatments, and two respiratory drugs.
A new study may help explain why women are more prone than men to a form of liver damage by implicating the hormone estrogen in the development of autoimmune hepatitis. The study reveals that estrogen and interleukin-6 collude to form a powerful duo that leads to immune cell misconduct.
Bayer has agreed to buy California-based Conceptus for around $1.1 billion to expand the kinds of birth control it offers. Conceptus makes Essure, an irreversible birth control method in which small metal and polyester coils are inserted to block a woman's fallopian tubes.
Actavis Inc. and Purdue Pharma LP are settling a patent dispute, and Actavis will be able to sell a generic abuse-resistant version of Purdue's painkiller OxyContin starting in 2014. Actavis expects more than $100 million in gross profit from generic OxyContin sales through 2015.